This book examines the application of stem cell surgery for diabetes and heart failure.
Organized into two sections, the first identifies and summarizes the current worldwide stem cell trials for heart failure. Subsequent chapters in part two analyze the current worldwide stem cell trials in patients with Diabetes Mellitus. Both sections utilize studies that include non-expanded stem cells; each study is grouped by stem cell type and geographic location.
Stem Cell Surgery Trials in Diabetes and Heart Failure is a comprehensive, convenient reference for cardiologists, endocrinologists, internists, and family physicians.
Author(s): Jeffrey N. Weiss
Publisher: Springer
Year: 2022
Language: English
Pages: 163
City: Cham
Preface
Contents
Part I: Heart Failure (United States)
Chapter 1: Bone Marrow-Derived Mesenchymal Stem Cells in Improving Heart Function in Patients with Heart Failure Caused by Anthracyclines
Chapter 2: Donor Bone Marrow-Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients with Cardiomyopathy Caused by Anthracyclines
Chapter 3: The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial
Chapter 4: Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFPEF Patients Treated with Allogeneic CDCs
Chapter 5: Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Part II: Heart Failure (Europe)
Chapter 6: Allogeneic Stem Cell Therapy in Heart Failure
Chapter 7: Stem Cell Therapy in Advanced Heart Failure
Chapter 8: Stem Cell Therapy in Ischemic Non-treatable Cardiac Disease
Chapter 9: Infusion Intracoronary of Mononuclear Autologous Adult Non Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients with Idiopathic Dilated Cardiomyopathy and Heart Failure
Chapter 10: Cell Therapy in HFpEF
Chapter 11: Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-Derived Mononuclear Cells on Mortality in Patients with Chronic Post-infarction Heart Failure
Chapter 12: Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients with STEMI
Chapter 13: Stem Cell Therapy in Non-ischemic, Non-treatable Dilated Cardiomyopathies II: A Pilot Study
Part III: Heart Failure (Iran)
Chapter 14: IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients
Chapter 15: ICMNC-HF: IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients
Part IV: Heart Failure (China)
Chapter 16: Treating Heart Failure with hPSC-CMs
Part V: Diabetes Mellitus: Type 1 Diabetes (United States)
Chapter 17: Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Chapter 18: A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
Chapter 19: Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Chapter 20: Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
Part VI: Diabetes Mellitus: Type 1 Diabetes (China)
Chapter 21: Stem Cell Educator Therapy in Diabetes
Chapter 22: Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy
Part VII: Diabetes Mellitus: Type 1 Diabetes (China/Spain)
Chapter 23: Stem Cell Educator Therapy in Type 1 Diabetes
Part VIII: Diabetes Mellitus: Type 1 Diabetes (South America)
Chapter 24: Mesenchymal Stem Cells in Patients with Type 1 Diabetes Mellitus
Part IX: Diabetes Mellitus: Type 1 Diabetes (Canada)
Chapter 25: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Part X: Diabetes Mellitus: Type 1 Diabetes (Middle East)
Chapter 26: Mesenchymal Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Patients (MSCTXT1DM)
Chapter 27: Use of Stem Cells in Diabetes Mellitus Type 1
Part XI: Diabetes Mellitus: Type 1 Diabetes (Sweden)
Chapter 28: Wharton’s Jelly-Derived Mesenchymal Stromal Cell-Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes
Part XII: Diabetes Mellitus: Type 2 Diabetes (United States)
Chapter 29: Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial Dysfunction in Diabetic Subjects (ACESO)
Chapter 30: Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
Part XIII: Diabetes Mellitus: Type 2 Diabetes (China)
Chapter 31: Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Type 2 Diabetes Mellitus
Chapter 32: Stem Cell Educator Therapy in Diabetes
Chapter 33: Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy
Part XIV: Diabetes Mellitus: Type 2 Diabetes (Near East)
Chapter 34: BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients
Part XV: Diabetes Mellitus: Type 2 Diabetes (Vietnam)
Chapter 35: BM-MNC and UC-MSC Infusion for Type 2 Diabetes Mellitus Patients (T2DM)
Part XVI: Other Thoughts
Chapter 36: Conclusion
References
Index
